Mike Sullivan Named President Of Avion Pharmaceuticals

ATLANTA, March 12, 2014 /PRNewswire/ -- Avion Pharmaceuticals, a specialty pharmaceutical company, recently announced the promotion of Mike Sullivan to the position of President.

Sullivan joined Avion Pharmaceuticals in 2011 as Vice President of Sales and Marketing. Tapped for his expertise in building corporate "start-up" pharmaceutical organizations, he has been instrumental in the commercial development, infrastructure and successful launch of Avion over the past three years.

Through his extensive experience and proficiency in sales management, managed care, trade, sales operations, product management, and training, Mike has spearheaded eight product launches in the span of Avion's brief history while also re-launching the Prenate® Prenatal Vitamin Family, the makers of Prenate® Mini trusted to support women's prenatal health and nutrition for more than 30 years. Avion is now positioned well within the prenatal vitamin category, ranking in the top-three prescription prenatal vitamins.

Sullivan's career history has included senior management positions with UCB Pharma, Novartis, Sanofi and Ther-Rx Pharmaceuticals.

"I am pleased to announce Mike's promotion and applaud his inexhaustible dedication to drive continuous success for Avion Pharmaceuticals. Mike exhibits endless passion in realizing our strategic mission to be the leading pharmaceutical company in the U.S. devoted to women's healthcare. With Mike's leadership, Avion is positioned to continue our growth through innovation by providing women and babies with products and support needed to live healthy and rewarding lives," said Mark Pugh, CEO for Avion Pharmaceuticals.

About Avion Pharmaceuticals, LLC.
Avion Pharmaceuticals, LLC. is a Specialty Pharmaceutical company formed to develop and market a portfolio of innovative pharmaceutical products in the Women's Heath and Dermatology therapeutic area. Avion Pharmaceuticals focuses on identifying opportunities to acquire and enhance the market potential of innovative, commercially available therapeutics and late-stage development drugs to fulfill unmet medical needs. For additional information about Avion Pharmaceuticals please contact the company at 678-325-5188.

SOURCE Avion Pharmaceuticals, LLC.

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.